Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.826 EUR | +1.49% | -6.96% | -19.44% |
06-04 | Pfizer: article on Lyme vaccine in The Lancet | CF |
06-04 | Valneva: article on Lyme vaccine in The Lancet | CF |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 233.7 | 704.9 | 2,574 | 861.1 | 655.1 | 538.2 | - | - |
Enterprise Value (EV) 1 | 195.5 | 553.9 | 2,286 | 670.5 | 737.8 | 616 | 632.4 | 654.1 |
P/E ratio | -129 x | -10.9 x | -32.7 x | -5.02 x | -6.47 x | 35.2 x | -49.9 x | -20.7 x |
Yield | - | - | - | - | - | - | 0.26% | - |
Capitalization / Revenue | 1.85 x | 6.39 x | 7.4 x | 2.38 x | 4.26 x | 2.83 x | 2.3 x | 1.67 x |
EV / Revenue | 1.55 x | 5.02 x | 6.57 x | 1.86 x | 4.8 x | 3.24 x | 2.71 x | 2.03 x |
EV / EBITDA | 25.1 x | -12.3 x | -48.5 x | -9.69 x | -11.3 x | 12.3 x | -26 x | -258 x |
EV / FCF | -36.5 x | 4.68 x | -140 x | -2.44 x | -3.4 x | -28.6 x | -634 x | 190 x |
FCF Yield | -2.74% | 21.4% | -0.71% | -41% | -29.4% | -3.5% | -0.16% | 0.53% |
Price to Book | 1.73 x | 9.09 x | 15.1 x | - | 5.1 x | 3.11 x | 4.57 x | 5.42 x |
Nbr of stocks (in thousands) | 90,920 | 90,958 | 105,078 | 138,355 | 138,788 | 139,153 | - | - |
Reference price 2 | 2.570 | 7.750 | 24.50 | 6.224 | 4.720 | 3.868 | 3.868 | 3.868 |
Announcement Date | 2/27/20 | 2/25/21 | 2/3/22 | 3/23/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 126.2 | 110.3 | 348.1 | 361.3 | 153.7 | 190 | 233.6 | 321.8 |
EBITDA 1 | 7.8 | -45.2 | -47.1 | -69.2 | -65.24 | 49.92 | -24.3 | -2.532 |
EBIT 1 | -0.811 | -55.12 | -61.4 | -113.4 | -82.09 | 27.48 | -31.77 | -11.95 |
Operating Margin | -0.64% | -49.97% | -17.64% | -31.4% | -53.4% | 14.46% | -13.6% | -3.71% |
Earnings before Tax (EBT) 1 | -0.87 | -65.3 | -69.98 | -144.8 | -98.63 | -0.9092 | -47.79 | -18.11 |
Net income 1 | -1.7 | -64.4 | -73.4 | -143.3 | -101.4 | 6.721 | -29.08 | -22.63 |
Net margin | -1.35% | -58.39% | -21.09% | -39.66% | -65.99% | 3.54% | -12.45% | -7.03% |
EPS 2 | -0.0200 | -0.7100 | -0.7500 | -1.240 | -0.7300 | 0.1100 | -0.0775 | -0.1867 |
Free Cash Flow 1 | -5.355 | 118.3 | -16.27 | -274.7 | -217 | -21.57 | -0.9976 | 3.439 |
FCF margin | -4.24% | 107.22% | -4.67% | -76.02% | -141.16% | -11.35% | -0.43% | 1.07% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | 0.0100 | - |
Announcement Date | 2/27/20 | 2/25/21 | 2/3/22 | 3/23/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 47.91 | 278.3 | 21.8 | 71.4 | 93.2 | 156.7 | 111.4 | 33.51 | 40.19 | 38.07 | 41.9 | 32.75 | 41.38 | 43.63 | 55.36 |
EBITDA | - | 12.54 | -13.3 | -122.7 | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -21.93 | 11.1 | -18.4 | -128.8 | -147.2 | 93.32 | -56.35 | -16.57 | -20.28 | -22.21 | -24.91 | 68.21 | -18.62 | -18.85 | -18.27 |
Operating Margin | -45.77% | 3.99% | -84.4% | -180.39% | -157.94% | 59.55% | -50.58% | -49.46% | -50.46% | -58.35% | -59.45% | 208.25% | -45% | -43.2% | -33% |
Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | - | - | - | - | - | -31.23 | -32.12 | -31.65 |
Net income 1 | - | - | - | - | - | - | - | - | - | - | - | - | -31.23 | -32.12 | -31.65 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -75.48% | -73.62% | -57.17% |
EPS 2 | - | - | - | - | - | - | - | -0.1300 | -0.1200 | -0.2500 | -0.2300 | 0.4100 | -0.0800 | -0.1100 | -0.1000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/4/20 | 2/3/22 | 5/5/22 | 8/11/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/4/23 | 9/21/23 | 11/9/23 | 3/21/24 | 5/7/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 82.7 | 77.8 | 94.2 | 116 |
Net Cash position 1 | 38.1 | 151 | 289 | 191 | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -1.268 x | 1.558 x | -3.875 x | -45.75 x |
Free Cash Flow 1 | -5.36 | 118 | -16.3 | -275 | -217 | -21.6 | -1 | 3.44 |
ROE (net income / shareholders' equity) | -1.25% | -60.6% | -59.2% | -73.4% | -58.3% | 16% | -37.9% | -17.9% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 1.490 | 0.8500 | 1.620 | - | 0.9300 | 1.240 | 0.8500 | 0.7100 |
Cash Flow per Share 2 | 0.0600 | 0.9500 | - | -0.8600 | - | -0.1000 | -0.1000 | 0.1000 |
Capex 1 | 10.5 | 18.9 | 92.2 | 29.2 | 14.2 | 13.9 | 11.7 | 9.32 |
Capex / Sales | 8.32% | 17.17% | 26.49% | 8.09% | 9.26% | 7.34% | 4.99% | 2.9% |
Announcement Date | 2/27/20 | 2/25/21 | 2/3/22 | 3/23/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- VLA Stock
- AYJ Stock
- Financials Valneva